Polycystic Ovary Syndrome: Multidisciplinary Care Approaches

Abstract

Polycystic Ovary Syndrome (PCOS) is one of the most prevalent endocrine disorders affecting women of reproductive age globally. Characterized by a spectrum of clinical manifestations, including ovulatory dysfunction, hyperandrogenism, and polycystic ovarian morphology, PCOS requires a nuanced, multidisciplinary approach for optimal care. This review synthesizes current evidence on the epidemiology, pathophysiology, risk factors, clinical features, diagnostic criteria, and comprehensive management of PCOS, integrating guideline-based recommendations and recent advances. The importance of coordinated care involving endocrinologists, gynecologists, dermatologists, dietitians, and mental health professionals is emphasized, with attention to individualized patient-centered strategies that address both metabolic and reproductive health outcomes.

Introduction

Polycystic Ovary Syndrome is a complex, heterogeneous disorder with significant reproductive, metabolic, and psychological sequelae. It is increasingly recognized as a major public health challenge due to its association with infertility, insulin resistance, type 2 diabetes mellitus, cardiovascular disease, and impaired quality of life. Multidisciplinary management is essential for guiding evidence-based interventions and improving long-term patient outcomes. This review aims to provide clinicians with an up-to-date synthesis of the clinical, pathophysiological, and therapeutic aspects of PCOS, grounded in recent literature and global guidelines.

Epidemiology / Disease Burden

PCOS affects approximately 6-20% of women of reproductive age, varying by diagnostic criteria and ethnicity. The Rotterdam criteria, NIH criteria, and Androgen Excess-PCOS Society guidelines contribute to heterogeneity in reported prevalence. PCOS is a leading cause of anovulatory infertility and is associated with increased risks of metabolic syndrome (up to 40%), impaired glucose tolerance (31%), and type 2 diabetes (up to 10-fold increased risk compared to age-matched controls). The disorder imposes a substantial psychosocial and economic burden, with increased rates of anxiety, depression, and healthcare utilization.

Pathophysiology

The etiopathogenesis of PCOS is multifactorial, involving genetic predisposition, environmental factors, and complex hormonal dysregulation. Hyperandrogenism, often central to PCOS, results from excess ovarian and/or adrenal androgen production due to enhanced luteinizing hormone (LH) secretion and insulin-mediated theca cell stimulation. Insulin resistance, present in up to 70% of PCOS patients regardless of BMI, exacerbates hyperandrogenism and contributes to metabolic complications. Dysregulation of gonadotropin-releasing hormone (GnRH) pulsatility, altered adipokine secretion, and low-grade chronic inflammation further complicate the pathophysiological landscape.

Risk Factors

Risk factors include familial aggregation, with heritability estimates up to 70%. Obesity, particularly central adiposity, amplifies the severity of PCOS symptoms and metabolic complications. Ethnic variations influence phenotypic expression and metabolic risks, with South Asian women exhibiting higher rates of insulin resistance. Environmental exposures, including endocrine-disrupting chemicals and lifestyle factors such as sedentary behavior and poor diet, are implicated in disease onset and progression.

Clinical Features

PCOS presents with a spectrum of signs and symptoms: menstrual irregularities (oligo- or amenorrhea), clinical and/or biochemical hyperandrogenism (hirsutism, acne, alopecia), and polycystic ovarian morphology on ultrasound. Metabolic features include insulin resistance, dyslipidemia, obesity, and increased cardiovascular risk. Psychological comorbidities - anxiety, depression, and reduced health-related quality of life are common and often underrecognized.

Diagnosis

The Rotterdam criteria require two of the following: oligo/anovulation, clinical/biochemical hyperandrogenism, or polycystic ovaries on ultrasound (11). Differential diagnoses such as congenital adrenal hyperplasia, androgen-secreting tumors, and thyroid dysfunction must be excluded. Laboratory evaluation includes serum total and free testosterone, sex hormone-binding globulin, LH, FSH, fasting glucose, oral glucose tolerance testing, and lipid profile. Pelvic ultrasonography is used to assess ovarian morphology, with ≥12 follicles (2–9 mm) and/or ovarian volume >10 mL considered diagnostic.

Treatment & Management

Multidisciplinary management targets reproductive, metabolic, dermatologic, and psychological domains. First-line therapy for overweight/obese women is lifestyle intervention - caloric restriction, increased physical activity, and behavioral modification—demonstrated to restore ovulation and improve metabolic parameters. Pharmacological treatment includes combined oral contraceptives for menstrual regulation and hyperandrogenism, metformin for insulin sensitization and metabolic risk reduction, and antiandrogens for hirsutism when contraception is ensured. Ovulation induction agents (letrozole preferred over clomiphene) are recommended for infertility. Dermatological management may involve topical agents and cosmetic approaches. Psychological support is vital, with referral to mental health services as needed.

Recent Advances / Emerging Therapies

Emerging therapies focus on novel insulin sensitizers (incretin-based therapies, thiazolidinediones), anti-androgenic agents (finasteride, flutamide, spironolactone), and inositol supplementation. Bariatric surgery is considered for morbidly obese women with refractory metabolic complications. Advances in reproductive technology, including in vitro maturation and individualized ovarian stimulation protocols, are improving fertility outcomes. Ongoing research explores the role of the gut microbiome, chronic inflammation, and precision medicine approaches in PCOS management.

Guideline Recommendations

International guidelines (Endocrine Society, ESHRE/ASRM, AE-PCOS) consistently advocate for a multidisciplinary, individualized approach. Lifestyle modification remains central, with pharmacologic interventions tailored to symptomatology and reproductive goals. Annual screening for metabolic and cardiovascular comorbidities is recommended. Psychological assessment and support should be routine. Shared decision-making and patient education are emphasized to enhance adherence and long-term outcomes.

Conclusion

PCOS is a complex and multifaceted endocrine disorder that requires coordinated, multidisciplinary care to effectively address its reproductive, metabolic, and psychological dimensions. As one of the most common hormonal disorders affecting women of reproductive age, PCOS presents with a diverse range of clinical manifestations, including menstrual irregularities, hyperandrogenism, infertility, obesity, insulin resistance, and an increased risk of long-term cardiometabolic complications. In addition to its physical health consequences, PCOS can significantly impact emotional well-being, self-esteem, body image, and overall quality of life, making comprehensive management essential. Successful treatment often involves collaboration among gynecologists, endocrinologists, primary care physicians, nutritionists, mental health professionals, and other healthcare providers to ensure holistic and individualized patient care.

Clinicians must remain informed about evolving scientific evidence, emerging therapeutic options, and updated international guideline recommendations to deliver effective, patient-centered management. Current approaches emphasize lifestyle modification, weight management, metabolic risk reduction, fertility optimization, and psychological support tailored to individual patient goals and symptom profiles. Advances in understanding the pathophysiology of PCOS continue to drive the development of more targeted diagnostic and therapeutic strategies. Continued research into genetic, metabolic, hormonal, and environmental contributors to the syndrome, along with innovations in treatment and care delivery, will further refine management pathways, improve long-term health outcomes, and enhance the quality of life for women living with PCOS across all stages of life.